Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Therapy Areas

Cardiovascular

Set Alert for Cardiovascular

Latest From Cardiovascular

Heart Failure Pipeline Review: Amgen's Omecamtiv And Merck's Vericiguat Step Up To Plate

In addition to small molecules, stem cell therapies promise to help rejuvenate the chronic heart failure pipeline, but high prices and invasive procedures may limit their use to end-stage patients, and skepticism about efficacy persists.

Cardiovascular Research & Development

Lilly's Basaglar, Crestor Generics Helped Hold Down Drug Spending Growth In 2017

Express Scripts' annual drug trend report highlights impact of key follow-on launches, and its own management solutions programs, in limiting the growth in overall drug spending for commercial plans to 1.5%; forecast calls for double-digit growth in inflammatory category to continue at least the next three years until biosimilar savings kick in.

Generic Drugs Biosimilars

Eight Clinical Trial Read-Outs To Look Out For In Early 2018

The first three months of the year should bring late-stage clinical trial read-outs for a range of novel products including Johnson & Johnson's esketamine, Esperion's bempedoic acid, ImmuPharma's Lupuzor and VBL's gene therapy for brain cancer.

Clinical Trials Research & Development

Managing Expectations: "We're Still On Target" Says AstraZeneca CEO

Pascal Soriot says AstraZeneca remains on track to hit its $45bn sales target in 2023 – more or less - but to do that the UK's second biggest drug maker must maintain recent improvements in R&D productivity.

Clinical Trials Sales & Earnings

AstraZeneca Links With Alibaba And Tencent In China 'Digital Health' Push

AstraZeneca agreed two new deals with Chinese tech groups Alibaba and Tencent as it tries to expand business in modernizing China, now the UK drug maker's second-largest market after the US.

Business Strategies Artificial Intelligence

AstraZeneca's Lokelma To Join Veltassa In Hyperkalemia Sector

The treatment of hyperkalemia in Europe in patients with chronic kidney disease or chronic heart failure looks set to become more vibrant, with AstraZeneca's Lokelma likely to join Vifor Pharma's Veltassa in the marketplace.

Renal Cardiovascular
See All

CNS

Set Alert for CNS

Latest From Neurology

US FDA Advisory Cmte. Review Of Charleston's Hydexor Exposes Flaws In Commercial Strategy

Physicians may be hesitant to prescribe the opioid/anti-emetic combo for several reasons; panelists were concerned the company hasn't figured out a specific commercial audience for Hydexor at this point in the review process.
Advisory Committees Neurology

BrainStorm Cell Therapeutics Seeks JVs And Investors To Commercialize Stem Cell Pipeline

Chaim Lebovits, president and CEO of BrainStorm Cell Therapeutics, discusses the company's stem cell trials in ALS and other ventures in the pipeline.
StartUps and SMEs Regenerative Medicine

Takeda Catches Rising Tide Of Antisense Neuroscience R&D

Huntington's disease is one of several genetically defined neurological diseases that are being targeted in a multibillion-dollar collaboration forged between the US's Wave Life Sciences and Japan's Takeda, that could include co-commercialization by the biotech in the US.

Deals Neurology

AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies

Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.
Research & Development Deals

Ipsen CEO To Feed Group's Three Therapeutic Engines Fresh Assets In 2018

CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.

Business Strategies Commercial

Biogen Spooks With Phase III Aducanumab Changes

Recruiting more patients into a trial to retain statistical power is standard practice, but with other companies discontinuing late-stage investigational Alzheimer's therapies, the difficulty in maintaining confidence in the development of new therapies for the condition has been underlined by investor responses to Biogen's alterations.

Neurology Clinical Trials
See All

Immunology

Set Alert for Immunology

Latest From Immune Disorders

Aimmune Accelerates Commercial Planning For Peanut Allergy Drug

Even better than expected efficacy and safety in the Phase III PALISADE trial puts Aimmune on track to file its BLA for peanut protein capsule AR101 by the end of 2018.

Clinical Trials Immune Disorders

GeNeuro Homes In On Ancestral Viral Genes To Treat Autoimmune Diseases

Focusing on an idea that many autoimmune diseases are caused by proteins from viral genes that are now embedded in human DNA, Swiss biotech GeNeuro is using the idea to develop therapeutics.
StartUps and SMEs Research and Development Strategies

Orchard Therapeutics Banks On Lentiviral Gene Therapy Potential

Armed with $110m raised in a Series B financing at the end of 2017, UK biotech Orchard Therapeutics is accelerating its efforts to lentiviral gene therapeutics into patients. 

Research & Development Immune Disorders

Theravance Banks $100m As J&J Bets Big On IBD Drug

If the JAK inhibitor codenamed TD-1473 proves effective in Crohn’s disease and ulcerative colitis, the clinical, regulatory and commercial know-how in IBD from partner Janssen could help Theravance pocket $1bn.

Immune Disorders Research & Development

Interview: Sandoz CEO On Biosimilars And Reshaping US Business

Observers were left surprised by the size of the decline in US sales at Sandoz during the fourth quarter. Richard Francis, CEO of Novartis' generics division, told Scrip about plans to turn the business around in which biosimilars will figure largely.

Biosimilars Business Strategies

Novartis' Cosentyx Goes Head-To-Head With Humira

With the initiation of EXCEED and SURPASS, Novartis is aiming to challenge Humira’s status as the preferred first-line biologic for ankylosing spondylitis and psoriatic arthritis.

Clinical Trials Biosimilars
See All

Infectious

Set Alert for Infectious Diseases

Latest From Infectious Diseases

Hansa Medical's 'Game Changer' In Transplantations May Have Other Uses Too

Hansa Medical AB, a Swedish-listed, clinical-stage biotech, is focused on developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases that could change the face of kidney transplants.

Clinical Trials Commercial

Bavarian Nordic CEO Says Likely To Sell Imvamune Priority Review Voucher

Danish group believes its smallpox vaccine will get approved, generate a transferable priority review voucher, and replace the current US-licensed replicating smallpox vaccine ACAM2000.

Business Strategies Clinical Trials

RSV Market: An Unmet Clinical Need For ReViral, And Big Pharma Too

The market landscape for drugs against respiratory syncytial virus infections, an important risk factor in premature infants and the immunocompromised, may change drastically in the future with numerous potential therapies in the pipeline.

Clinical Trials Research & Development

Gilead's Biktarvy Approval Heightens HIV Competition With ViiV

Gilead hopes Biktarvy will enable it to win market share away from ViiV's dolutegravir-containing regimens, but ViiV filed a patent infringement case within hours of the US FDA approval of Gilead's new combo.

Approvals Life Cycle Management

Gilead's CAR-T Therapy Yescarta Slowly Getting Off The Ground

Slow and steady approach to launch should position Yescarta well in the long run, Gilead maintains – the CAR-T therapy brought in $7m in its first month. But Gilead is still suffering from the decline in hepatitis C.

Sales & Earnings ImmunoOncology

10 First Approvals To Look Out For In 2018

Another hectic 12 months are anticipated at the US FDA as it is set to give its verdict on no fewer than 40 products in 2018. Here Scrip takes a look at 10 of the more interesting candidates approaching the market for the first time.

Approvals Commercial
See All

Metabolic

Set Alert for Metabolic

Latest From Metabolic Disorders

Novo Nordisk's Oral Semaglutide Succeeds In First Phase III, But Prompts Questions

In PIONEER 1, weight loss results for the oral version of the GLP-1 agonist were somewhat disappointing and lack of detail in the top-line release prompts concerns about compliance.

Clinical Trials Metabolic Disorders

Can Sanofi’s Toujeo Prickle Tresiba In India?

Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.

India Pricing Strategies

Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant

France's Poxel has completed the out-licensing of its oral Phase III-ready diabetes therapy, the glimin, imeglimin, that could be transformative for both the biotech and the US and European licensee, Roivant Sciences.

Deals Metabolic Disorders

Lilly's Basaglar, Crestor Generics Helped Hold Down Drug Spending Growth In 2017

Express Scripts' annual drug trend report highlights impact of key follow-on launches, and its own management solutions programs, in limiting the growth in overall drug spending for commercial plans to 1.5%; forecast calls for double-digit growth in inflammatory category to continue at least the next three years until biosimilar savings kick in.

Generic Drugs Biosimilars

Eight Clinical Trial Read-Outs To Look Out For In Early 2018

The first three months of the year should bring late-stage clinical trial read-outs for a range of novel products including Johnson & Johnson's esketamine, Esperion's bempedoic acid, ImmuPharma's Lupuzor and VBL's gene therapy for brain cancer.

Clinical Trials Research & Development

Managing Expectations: "We're Still On Target" Says AstraZeneca CEO

Pascal Soriot says AstraZeneca remains on track to hit its $45bn sales target in 2023 – more or less - but to do that the UK's second biggest drug maker must maintain recent improvements in R&D productivity.

Clinical Trials Sales & Earnings
See All

Oncology

Set Alert for Oncology

Latest From Cancer

Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform

Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Deals Business Strategies

Think Positive: Clovis Confident Of CHMP Okay For Rubraca

The US biotech expects to finally get its PARP inhibitor for ovarian cancer onto the European market in the next few months to compete with rivals AstraZeneca and Tesaro after the CHMP "communicated a positive trend vote" ahead of an opinion being issued next month.

Cancer Drug Review

Merck & Co's Viralytics Buy Puts Oncolytic Viruses Back In Spotlight

The US major is spending $394m to get hold of Cavatak, an immunotherapy that it hopes will work well in combination with the anti-PD-1 blockbuster Keytruda.

ImmunoOncology M & A

Roche To Build RWE Cancer Data Extraction Role With Flatiron Buy

Acquisition reflects that regulatory-grade real-world evidence will play increasing role in drug discovery, development, commercialization and reimbursement.

Business Strategies Commercial

Exploring Sanofi's Revamped IO Pipeline

In an exclusive interview, Sanofi's head of oncology development Joanne Lager explains how the French big pharma could make a comeback in cancer this year and highlights its immunotherapy combination opportunities.

Business Strategies ImmunoOncology

AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval

Unlike other indications PD-1/L1 inhibitors are shooting for, Stage III non-small cell lung cancer is an untapped market and AstraZeneca will have the space to itself for a while.
ImmunoOncology Cancer
See All

Respiratory

Set Alert for Respiratory

Latest From Respiratory

Compliance Continues To Curtail Effective Asthma Treatment

The top two high-priority challenges to address in asthma treatment for respondents to a large survey by Datamonitor Healthcare of pulmonologists and primary care physicians in the US, Japan and Europe were improving compliance and developing effective, easy-to-use inhalers.

Respiratory Compliance

Santhera Expands Pipeline With Polyphor Cystic Fibrosis Deal

Santhera has moved into cystic fibrosis via a global licensing deal with Polyphor, expanding its rare disease pipeline.

Rare Diseases Deals

Vertex Eyes Triple Glory After Hat Trick of CF Approvals

Symdeko, which will have a wholesale price of $292,000 per year, has got the green light in the US, adding to Vertex' already-approved cystic fibrosis treatments Kalydeco and Orkambi. Now, focus will shift onto its role in potential triple combinations for the disease.

Rare Diseases Approvals

Three Strikes For Generic Advair With An FDA CRL For Sandoz

Novartis' generic drug unit confirmed the receipt of a complete response letter from the US FDA for a generic version of GlaxoSmithKline's Advair, following similar CRLs for Mylan and Hikma.

Generic Drugs Complete Response Letters

Walmsley: GSK Is 'Prepared' And 'Ready' For US Advair Generic Launch

GlaxoSmithKline is poised for a challenging 2018, with an interchangeable Advair generic expected to launch, but GSK believes growth from new products will make up some of the loss. US Advair sales could be slashed to £750m from £1.6bn in 2017.

Sales & Earnings Business Strategies

AstraZeneca Links With Alibaba And Tencent In China 'Digital Health' Push

AstraZeneca agreed two new deals with Chinese tech groups Alibaba and Tencent as it tries to expand business in modernizing China, now the UK drug maker's second-largest market after the US.

Business Strategies Artificial Intelligence
See All
UsernamePublicRestriction

Register